Navigation Links
Potential new drug candidate found for Alzheimer's disease
Date:5/31/2011

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid (Aβ) in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

A paper detailing the findings has been published as an early online version and is scheduled for publication in the September 6 issue of the Journal of Alzheimer's Disease.

According to lead investigator Vivian Y. H. Hook, PhD, professor of the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences and professor of neurosciences, pharmacology and medicine at the UCSD School of Medicine, this is major news for scientists studying Alzheimer's disease.

"The finding is especially exciting because E64d has previously been shown safe for use in humans, so we believe the compound has strong potential as a new therapy for Alzheimer's disease," said Hook.

Increased Aβ levels in the brain are associated with the development of memory loss and amyloid plaque, the hallmark of Alzheimer's disease. Aβ peptides are "cut" out from a larger protein called the amyloid precursor protein (APP) by an enzymatic "scissor" called β-secretase, and aggregate to form plaques in the brain regions responsible for memory.

E64d reduces Aβ by inhibiting the β-secretase "scissors" from "cutting" the APP chain into smaller toxic Aβ peptides. But in this study, the researchers found that the compound actually increases the activity of a protease called BACE1 which, to date, has been regarded as the primary β-secretase. Instead, E64d appears to lower brain Aβ by inhibiting the β-secretase activity of another protease, Cathepsin B.

"The study indicates Cathepsin B as a new target for therapeutic inhibition of Aβ production and subsequent improved memory function," said Hook. "This is an important finding because we show that β-secretase inhibition can occur with Cathepsin B inhibition and without BACE1 inhibition."

The researchers studied both old and young transgenic Alzheimer's disease mice, and found that memory loss improved in both. In young mice, feeding E64d prevented development of memory loss; in old mice with memory loss, it improved memory.

The study builds upon work published in March 2008 that first demonstrated that inhibitors of Cathepsin B resulted in improved memory and reduction of Aβ and amyloid plaque; but in that study, the drug was administered directly into the brains of AD mice. In the new study, oral administration of the drug was efficacious and could lead the way to clinical trials in humans.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. The Potential to Modify the Course of Parkinsons Disease
2. Potentially Toxic Flame Retardants Found in Baby Products
3. Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
4. Study shows pharmacies software systems miss potentially dangerous interactions
5. Experts explore digital technologies potential to improve health care
6. Most nurses dont use recommended intramuscular injection site despite potential risks
7. A potential novel drug-target for colorectal cancer treatment comes from the brain
8. Potential diagnostic test for Alzheimers would use cerebrospinal fluid
9. Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder
10. Accountable care organizations have potential to curb costs and improve health care
11. Potential new strategy to reduce catheter blockage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... financial consultation services to families and business owners in the Dalton region, is ... support for children overcoming sexual assault and physical abuse. , The GreenHouse is ...
(Date:7/21/2017)... ... July 21, 2017 , ... Adolfson ... renovate and improve the Ramsey County Medical Examiners Facility located in Saint Paul, ... $2.5 million project is scheduled to start in late 2017/early 2018. , ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm ... the contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces ... Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is ... clips in the FCPX timeline. This effect isolates horizontal and vertical lines of pixels ... contains either a rotating or flipping animation and can be changed using a drop-down ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... , July 21, 2017  Endo International plc ... completing a comprehensive review of its manufacturing network, the ... and distribution facilities in Huntsville, Alabama ... take place over the next 12 to 18 months. ... impacted by declining volumes of commoditized products and these ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/17/2017)... 17, 2017  MedX Holdings, Inc., the manufacturer and ... and rehabilitation equipment, today announced the national roll out ... considered the gold standard for the treatment of low ... strengthening equipment. How ... physician or practice who prescribe the MedX Home Back ...
Breaking Medicine Technology: